Afatinib: 42 Real Stories

42 stories match afatinib. 41 of them mention targeted therapy.

Cancer Stories

Carla, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Carla's Patient Story

Patient Info: Carla, Female | Stage IV

Metastatic Site: brain

After repeated resistance and a serious episode involving a brain lesion and extensive fluid around the lung, Carla recovered and was stable without new symptoms on her eighth line of treatment.

LUNGevity
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated lung cancer responds after acquired ROS1 resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; acquired ROS1 rearrangement

Metastatic Site: pleura

She remained on osimertinib plus crizotinib with a sustained clinical and radiologic response for more than 18 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung CancerLung Cancer

EGFR R252C multifocal lung cancer responding to afatinib

Patient Info: Anonymized

Biomarkers: EGFR R252C extracellular-domain mutation

Afatinib was associated with suppression of primary tumor growth and extended progression-free survival in a patient with multifocal lung cancer and glioma driven by EGFR R252C. Stage and metastatic sites were not established from the available case summary.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR-mutated lung adenocarcinoma with suspected myocardial metastasis responding to afatinib plus chemotherapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR L861Q; PD-L1 TPS/CPS 65%. TP53, MET and PIK3CA alterations also reported.

Metastatic Site: left ventricular myocardium; mediastinal lymph nodes…

As of December 2025, the suspected left-ventricular myocardial metastasis had shrunk after 2 courses of afatinib plus pemetrexed/cisplatin, and the patient had no cardiovascular events during monitoring.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-Mutant Stage IV Lung Cancer Treated After Osimertinib-Related Lung Toxicity

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; later EGFR T790M resistance mutation

Metastatic Site: brain, lungs, bones, left adrenal gland, meninges

The latest documented treatment was a lower-dose osimertinib rechallenge with corticosteroids, which reduced the tumor without recurrence of the prior interstitial lung disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colorectal Cancer With NRG1 Fusion Controlled for Years With Afatinib

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: MATN-NRG1 fusion; no KRAS alteration detected

Afatinib controlled her metastatic colorectal cancer for 136 weeks. After resection of the remaining target lesion in September 2022, she remained alive with no progression as of October 2024.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

NRG1-Fusion Colorectal Cancer Progressing on Afatinib

Patient Info: Anonymized, female, 70+

Biomarkers: CD74-NRG1 fusion; no KRAS alteration detected

The cancer progressed clinically after 8 weeks on afatinib. She died in November 2021.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: liver

The cancer progressed after transformation to small cell lung cancer, and she died 49 months after the original diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

NRG1-Fusion Lung Cancer With a 24-Month Response to Afatinib

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRG1 fusion; KRAS/EGFR/ALK/ROS1/ERBB2 alterations not detected

Metastatic Site: left lung

Her cancer progressed during atezolizumab, and she died in May 2019.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Metastatic NRG1-Fusion Lung Cancer Responding to Long-Term Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CD74-NRG1 fusion

Metastatic Site: lungs

As of February 2020, she remained on afatinib 30 mg daily with an ongoing partial response after 27 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Right-Sided Colon Cancer With an NRG1 Fusion

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS mutation; POMK-NRG1 fusion

Metastatic Site: liver|lungs

He had persistent metastatic disease after 16 months of afatinib and entered a phase I trial in January 2020.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer With Unusual Colon Metastases After Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: EGFR exon 19 deletion

Metastatic Site: liver|adrenal glands|bone|brain|ascending…

The cancer progressed after an initial response to afatinib, with new brain and colon metastases. She died from respiratory failure on August 1, 2016.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Long response to afatinib in EGFR-mutated lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861Q mutation; EGFR G719X mutation

Metastatic Site: multiple bilateral ribs

CT at 30 months showed no recurrence, and he remained well 32 months after starting afatinib.

PubMed Central
OutcomeResponding Well